Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Dr. Zhu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Cardiovascular Disease, 2017 - 2020- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2014 - 2017
Case Western Reserve University School of MedicineClass of 2014
Certifications & Licensure
CA State Medical License 2016 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Clinical Trials
- Pilot Study for Black Men With Prostate Cancer: Optimization Of Mental and Heart Health, the BOOM-Heart Study Start of enrollment: 2021 Nov 18
Publications & Presentations
PubMed
- Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis.Yuhsin Vivian Huang, Yin Sun, Harrison Chou, Noah Wagner, Maria Rosaria Vitale
Circulation Research. 2025-02-28 - Classes of Antineoplastic Agents Associated with Increased Risk of Cancer Therapy-associated Hypertension and Management Strategies.Hoda Sayegh, Alexia Zagouras, Joel W Neal, Ronald M Witteles, Han Zhu
Cardiology Clinics. 2025-02-01 - 12 citationsImmune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure.Tamás G Gergely, Zsófia D Drobni, Marinos Kallikourdis, Han Zhu, Wouter C Meijers
Nature Reviews. Cardiology. 2024-07-01
Grant Support
- Investigating CXCR3 Blockade as Precision Therapy for Cardiac Sarcoidosis using Single-Cell Multi-omics and TCR PhenotypingSTANFORD UNIVERSITY2024–2029
- Investigating CXCR3 Blockade as Precision Therapy for Cardiac Sarcoidosis using Single-Cell Multi-omics and TCR PhenotypingSTANFORD UNIVERSITY2024–2029
- Investigating CXCR3 Blockade as Precision Therapy for Cardiac Sarcoidosis using Single-Cell Multi-omics and TCR PhenotypingSTANFORD UNIVERSITY2024–2029
- Investigating CXCR3 Blockade as Precision Therapy for Cardiac Sarcoidosis using Single-Cell Multi-omics and TCR PhenotypingSTANFORD UNIVERSITY2024–2029
- Investigating CXCR3 Blockade as Precision Therapy for Cardiac Sarcoidosis using Single-Cell Multi-omics and TCR PhenotypingSTANFORD UNIVERSITY2024–2029
- CXCL9/10 Macrophage Induced CXCR3+ T-cell Recruitment to the Heart Contributes to Immunotherapy MyocarditisSTANFORD UNIVERSITY2024–2026
- CXCL9/10 Macrophage Induced CXCR3+ T-cell Recruitment to the Heart Contributes to Immunotherapy MyocarditisSTANFORD UNIVERSITY2024–2026
- CXCL9/10 Macrophage Induced CXCR3+ T-cell Recruitment to the Heart Contributes to Immunotherapy MyocarditisSTANFORD UNIVERSITY2024–2026
- CXCL9/10 Macrophage Induced CXCR3+ T-cell Recruitment to the Heart Contributes to Immunotherapy MyocarditisSTANFORD UNIVERSITY2024–2026
- CXCL9/10 Macrophage Induced CXCR3+ T-cell Recruitment to the Heart Contributes to Immunotherapy MyocarditisSTANFORD UNIVERSITY2024–2026
- Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced MyocarditisSTANFORD UNIVERSITY2022–2026
- Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced MyocarditisSTANFORD UNIVERSITY2022–2026
- Gene regulatory programs drivingmetabolic maturation of human pluripotent stem cell derived β-cellsUNIVERSITY OF CALIFORNIA, SAN DIEGO2024–2025
- Gene regulatory programs drivingmetabolic maturation of human pluripotent stem cell derived β-cellsUNIVERSITY OF CALIFORNIA, SAN DIEGO2024–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
